ALEXANDRIA, Va. –– The American Society of Clinical Oncology (ASCO) has released a research statement, “Measuring Ovarian Toxicity in Clinical Trials,” outlining new recommendations for appropriate assessment of ovarian toxicity in cancer clinical trials. The statement, published today in Lancet Oncology, emphasizes the urgent need to understand the long-term impacts of cancer therapies on ovarian function.
October 2, 2023
September 28, 2023
ASCO has released a statement on the how an impending government shutdown will impact cancer research and scientific progress.
September 20, 2023
Three studies exploring interventions to improve the quality of life for patients with cancer will be highlighted in the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium’s official Press Program. The interventions included yoga-based supportive care, a virtual mind-body fitness program, and a text-based e-triage system.
September 14, 2023
The House Energy and Commerce Subcommittee on Health will hold a hearing today on several bills aimed at addressing the ongoing U.S. drug shortage crisis. Many of the bills contain provisions the Association for Clinical Oncology supports as effective means to mitigate and prevent drug shortages and promote a more resilient supply chain in the future.
September 5, 2023
The American Society of Clinical Oncology (ASCO) will join the President’s Cancer Panel on Sept. 7 to highlight the numerous ways ASCO is working to advance the National Cancer Plan and achieve the president’s Cancer Moonshot goal of “ending cancer as we know it.”
July 31, 2023
A combination of resistance and aerobic exercise may improve sexual function in patients with prostate cancer according to a new study conducted in Australia. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Breakthrough Meeting, taking place August 3-5 in Yokohama, Japan.
July 31, 2023
Researchers in Japan developed an artificial intelligence (AI)-based diagnostic tool for colposcopy examinations that can accurately identify cervical intraepithelial neoplasia (CIN)—abnormal cells found on the surface of the cervix that may become cancer and spread to nearby normal tissue—and suggest appropriate biopsy sites. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Breakthrough Meeting, taking place August 3-5 in Yokohama, Japan.
July 31, 2023
A new, multi-target stool DNA methylation assay accurately detected and identified the tissue of origin of multiple gastrointestinal (GI) cancers. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Breakthrough Meeting, taking place August 3-5 in Yokohama, Japan.
July 31, 2023
A non-invasive blood test successfully detected early-stage cancer and identified tumor location in asymptomatic individuals in Vietnam according to a new study. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Breakthrough Meeting, taking place August 3-5 in Yokohama, Japan.
July 24, 2023
In patients with wild-type TP53 advanced or recurrent endometrial cancer, the addition of maintenance therapy with selinexor following systemic therapy may prolong progression-free survival (PFS), according to research that will be presented during the July 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
July 18, 2023
The American Society of Clinical Oncology (ASCO) Breakthrough Meeting will convene oncology professionals from around the world in Yokohama, Japan, to explore cutting-edge advances in cancer care technology and innovations that can help transform care for people living with cancer.
July 18, 2023
ALEXANDRIA, Va. -- The American Society of Clinical Oncology (ASCO) has been awarded $11 million in research funding by the Patient-Centered Outcomes Research Institute (PCORI) to study dosing strategies of oral CDK4/6 inhibitors in older adults living with metastatic breast cancer. The study aims to address a critical evidence gap in the treatment of this disease: dose optimization and individualization. Despite breast cancer being more prevalent in people age 65 or older, few from this age group, particularly those above 75, are included in CDK4/6 inhibitor clinical trials.
July 7, 2023
The Department of Health and Human Services (HHS), Department of Labor and the Treasury Department issued a proposed rule regulating the availability of short-term limited duration insurance (STLDI) plans. The rule would restrict the availability of these plans to no more than four months.
June 6, 2023
Twenty studies exploring a wide range of topics across many cancer disease sites will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, IL, and online, June 2-6.
June 6, 2023
Results from the largest prospective study of primary mediastinal B-cell lymphoma show that radiation therapy can be omitted in patients who have a complete metabolic response after chemoimmunotherapy. The IELSG37 international study found that these patients may be spared from late toxicities without compromising the chances of cure. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
Pages |